Abstract
N-(4-hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid which reduces the incidence of experimental tumours in animals and has been chosen for its weak toxicity to be tested as a chemopreventive agent in humans. The mechanism of antineoplastic action is still unknown but a possible immunoenhancing effect may be postulated. We investigated the NK activity of PBMC from a group of women treated with 4-HPR as a part of a large scale randomised phase III trial on chemoprevention of contralateral disease in mastectomised women. After 180 days of treatment the NK activity was augmented 1.73 times as compared to that of patients given a placebo. The NK activity of PBMC from 4-HPR treated women is maximised, being higher than the basal and even the rIL-2 or alfa-rIFN stimulated activity of controls. For this reason in the majority of cases it cannot be further augmented by incubation with either rIL-2 or alfa-rIFN in vitro. The increased NK activity of 4-HPR treated women is not due to an enhanced production of endogenous IL-2, because PBMC cultures from patients treated with 4-HPR or placebo, incubated in vitro with a panel of different stimulators (recall antigens, PHA, allogeneic and xenogeneic cells) produce similar amounts of IL-2. The functional activity, but not the number of NK cells is increased in 4-HPR treated women. The mechanism by which 4-HPR stimulates NK activity is not a function of direct action on NK cells. Indeed incubation of PBMC from blood donors with 4-HPR or its major metabolite N-(4-methoxyphenyl) retinamide (4-MPR) does not modify their natural cytotoxicity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Formelli F., Carsana R., Costa A., Buranelli F., Campa T., Dossena G., Magni A., Pizzichetta M. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res. 1989 Nov 1;49(21):6149–6152. [PubMed] [Google Scholar]
- Fraker L. D., Halter S. A., Forbes J. T. Effects of orally administered retinol on natural killer cell activity in wild type BALB/c and congenitally athymic BALB/c mice. Cancer Immunol Immunother. 1986;21(2):114–118. doi: 10.1007/BF00199858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hultin T. A., May C. M., Moon R. C. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos. 1986 Nov-Dec;14(6):714–717. [PubMed] [Google Scholar]
- Jemma C., Arione R., Martinetto P., Forni G. Fluctuations of NK activity in human volunteers receiving vitamin A or a placebo daily. Boll Ist Sieroter Milan. 1986;65(5):386–393. [PubMed] [Google Scholar]
- Malter M., Schriever G., Eilber U. Natural killer cells, vitamins, and other blood components of vegetarian and omnivorous men. Nutr Cancer. 1989;12(3):271–278. doi: 10.1080/01635588909514026. [DOI] [PubMed] [Google Scholar]
- Peng Y. M., Dalton W. S., Alberts D. S., Xu M. J., Lim H., Meyskens F. L., Jr Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer. 1989 Jan 15;43(1):22–26. doi: 10.1002/ijc.2910430106. [DOI] [PubMed] [Google Scholar]
- Rotmensz N., De Palo G., Formelli F., Costa A., Marubini E., Campa T., Crippa A., Danesini G. M., Delle Grottaglie M., Di Mauro M. G. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer. 1991;27(9):1127–1131. doi: 10.1016/0277-5379(91)90309-2. [DOI] [PubMed] [Google Scholar]
- Sidell N., Famatiga E., Shau H., Golub S. H. Immunological aspects of retinoids in humans. III. Effects of retinoic acid on the natural killing of tumor cells. J Biol Response Mod. 1985 Jun;4(3):240–250. [PubMed] [Google Scholar]
- Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981 Apr;126(4):1393–1397. [PubMed] [Google Scholar]
- Villa M. L., Ferrario E., Bergamasco E., Bozzetti F., Cozzaglio L., Clerici E. Reduced natural killer cell activity and IL-2 production in malnourished cancer patients. Br J Cancer. 1991 Jun;63(6):1010–1014. doi: 10.1038/bjc.1991.219. [DOI] [PMC free article] [PubMed] [Google Scholar]